➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Moodys
Mallinckrodt
Harvard Business School

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIOCIGUAT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Riociguat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00855660 ↗ Effect of Riociguat on Bone Metabolism Completed Bayer Phase 1 2009-03-01 Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.
NCT01014247 ↗ Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation Completed Bayer Phase 1 2009-11-01 The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).
NCT01065051 ↗ Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics Terminated Bayer Phase 2 2010-11-01 The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
NCT01065454 ↗ A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction Active, not recruiting Bayer Phase 2 2010-04-01 The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riociguat

Condition Name

Condition Name for Riociguat
Intervention Trials
Hypertension, Pulmonary 13
Chronic Thromboembolic Pulmonary Hypertension 5
Ventricular Dysfunction, Left 3
Pulmonary Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Riociguat
Intervention Trials
Hypertension, Pulmonary 23
Hypertension 23
Familial Primary Pulmonary Hypertension 7
Ventricular Dysfunction, Left 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Riociguat

Trials by Country

Trials by Country for Riociguat
Location Trials
United States 113
Germany 62
Japan 35
Italy 24
Canada 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Riociguat
Location Trials
Pennsylvania 8
New York 8
Massachusetts 8
Ohio 7
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Riociguat

Clinical Trial Phase

Clinical Trial Phase for Riociguat
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Riociguat
Clinical Trial Phase Trials
Recruiting 16
Completed 9
Not yet recruiting 8
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riociguat

Sponsor Name

Sponsor Name for Riociguat
Sponsor Trials
Bayer 27
Merck Sharp & Dohme Corp. 3
Medical University of Vienna 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Riociguat
Sponsor Trials
Industry 34
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
AstraZeneca
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.